Drug intelligence / Profile preview

SCTT11

Development stage: Phase 2
Lead developer: Sinocelltech

Overview

SCTT11 is a drug currently undergoing a multicentre, randomized, double-blinded, placebo-controlled Phase I/II clinical study. Developed by Sinocelltech Ltd., this study aims to evaluate the drug's safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy. The primary indication being investigated is moderate-to-severe Thyroid Eye Disease, with the study enrolling both healthy participants and those affected by the condition.

Beyond the preview

Go deeper on SCTT11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCTT11.

Explore the full profile